P
harmacists play a vital role in the overall provision of patient care, from educating hospital staff about new medications and drug research to caring for a growing number of patients with complex disease states. Despite these daily demands, pharmacists remain committed to optimizing patient safety and offering innovative programs to better serve patients and other health care providers. When the Joint Commission updated its National Patient Safety Goals in 2008 to include reducing the likelihood of patient harm associated with anticoagulation therapy, 1 pharmacy practitioners at the Medical University of South Carolina (MUSC) recognized an opportunity to play a major role in guiding the appropriate management of direct thrombin inhibitor (DTI) therapy to improve patient safety and outcomes.
DTIs are considered the firstline option for anticoagulation Purpose. The impact of a collaborative drug therapy management (CDTM) agreement enabling pharmacist-managed direct thrombin inhibitor (DTI) therapy was evaluated. Methods. A retrospective chart review was conducted to compare selected outcome measures between cohorts of adults who received argatroban or bivalirudin therapy for suspected heparin-induced thrombocytopenia (HIT) before (n = 25) and after (n = 25) the implementation of an institutional DTI protocol under which properly trained and credentialed pharmacists have a primary role in dosing and monitoring DTI infusions. The primary endpoints were the mean time to attainment of activated partial thromboplastin time (aPTT) values in a specified therapeutic range and the proportion of total inpatient treatment time during which aPTT values were in that range. Secondary endpoints included the incidence of major and minor bleeding and the incidence of medication errors. Results. After implementation of the DTI protocol, therapeutic aPTT values were achieved more rapidly (a mean of 3.4 hours in the postimplementation cohort versus a mean of 7.7 hours in the preimplementation cohort, p = 0.009) and maintained more consistently. Rates of bleeding and overall mortality were similar in the two groups; the frequencies of documented medication errors were 12% and 40% in the postimplementation and preimplementation cohorts, respectively (p = 0.05). Conclusion. A pharmacist-driven DTI program resulted in improved effectiveness and safety outcomes, as demonstrated by improved attainment of target aPTT values and a decreased frequency of medication errors. Am J Health-Syst Pharm. 2012; 69:1993-8 in patients with heparin-induced thrombocytopenia (HIT).
2 However, currently there are no standard guidelines for the management of DTI infusions with dosage adjustments based on the activated partial thromboplastin time (aPTT) value. In order to optimally manage DTI Am J Health-Syst Pharm-Vol 69 Nov 15, 2012 infusions, clinical pharmacists at our institution developed a DTI therapy protocol involving argatroban and bivalirudin to be used in patients with HIT. 3 The purpose of this protocol was to provide guidelines to ensure the appropriate use, dosage, and monitoring of DTI therapy in the adult population, with the goals of decreasing medication errors and improving outcomes related to the effectiveness of the agents.
With the advent of the program, pharmacists were given the opportunity to become credentialed clinicians by meeting specific educational requirements and fulfilling the necessary responsibilities described for participation in a multidisciplinary collaborative drug therapy management (CDTM) agreement. In addition, clinical pharmacists introduced an inpatient "pharmacy-to-dose" policy, which redefined the role of a credentialed clinical pharmacist in making therapeutic decisions regarding DTI dosage adjustment and monitoring.
Before the development and implementation of the pharmacyto-dose policy and subsequent multidisciplinary DTI therapy management protocol, DTI infusions were primarily managed by pharmacists under the supervision of physicians. Problems with this process included unacceptably long intervals between the reporting of aPTT values and appropriate dosage adjustments, prescribing and administration errors, and, in some cases, failure to adjust infusion rates during evening and weekend shifts, when fewer clinical pharmacy staff are available. After an investigation of prescribing and administration practices, along with reported adverse events among patients on DTI therapy, it was clear that patient outcomes were not being optimized. Thus, a CDTM policy for the inpatient setting was developed to reduce opportunities for medication errors and disruption of patient care.
After the implementation of the CDTM service, pharmacists were able to better assist physicians in identifying patients with probable HIT; pharmacists were also able to better manage the dosing and monitoring of DTI therapy through collaboration efforts with nurses. In addition, with the advent of the pharmacist-driven protocol, credentialed pharmacists provided more complete communication to nurses and physicians while also including daily progress note documentation in the patient's chart regarding monitoring, dosage changes, and future plans for DTI therapy. To implement this policy, three major areas were addressed: credentialing of pharmacists, the ordering process, and appropriate documentation. 3 Over the past decade, a number of studies have been conducted to investigate the outcomes associated with CDTM services. However, the literature available to help guide CDTM anticoagulation services in an inpatient setting is somewhat limited. The purpose of the study described in this article was to compare the overall impact of the DTIfocused CDTM program in an inpatient setting in terms of effectiveness and safety outcomes.
Methods
The study described here was a retrospective cohort analysis of patients who received argatroban or bivalirudin before and after implementation of the CDTM program. A total of 50 patient cases were included in this study: the final 25 patients to receive either drug before implementation of the program and the first 25 patients treated with either drug after program implementation who met the inclusion criteria and were not excluded. The sample size was determined via a power analysis for detecting a 4-hour difference in the time to attainment of a target aPTT value. Patients were included if they were over the age of 18 years and received either argatroban or bivalirudin for suspected HIT. Patients receiving less than 24 hours of DTI therapy were excluded.
Data collected in this retrospective chart review included patient demographic data, the results of platelet factor 4 (PF4) testing and serotoninrelease assay (SRA), the number of blood transfusions required, aPTT measurements associated with argatroban and bivalirudin infusions, and nurse and physician documentation. Patient data were collected until the DTI was discontinued. Primary endpoints included the time to attainment of a target aPTT value and the amount of time the values remained within the target aPTT range. Secondary endpoints included the frequencies of major and minor bleeding and medication errors. Additional data collection and reporting included actual and expected hospital length of stay (LOS), intensive care unit LOS, and mortality; these data were collected through the University HealthSystem Consortium (UHC) database, which uses Medicare Severity-DiagnosisRelated Group data to estimate expected LOS and mortality. 4 This information was collected regardless of when a patient received a DTI.
The target aPTT range for argatroban and bivalirudin, defined before implementation of this protocol, was 50-80 seconds. The time to achievement of a target aPTT was defined as the time from the beginning of the DTI infusion to the first documented aPTT value within the target range. The percentage of time within the target aPTT range was the proportion of the total DTI treatment time during which aPTT values were within the target range, even if target-range values were nonconsecutive. Bleeding was defined as any documented bleed leading to a drop in the hemoglobin concentration of at least 2 g/dL and requiring transfusion of blood products. Major
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Medication errors were categorized as either prescribing or administration errors. Prescribing errors were defined as incorrect orders from a physician, including inappropriate dosage and incorrect adjustment of infusion rates. A dosage was considered inappropriate if it was inconsistent with the protocol-recommended initial dosage (indicated on the order form), which accounted for renal and hepatic dysfunctions. Administration errors included errors in setting or adjusting infusion rates, a lack of documentation of changes in infusion rates, and inappropriate initiation or discontinuation of DTI therapy. 
Results
The baseline demographics of the patients in the preimplementation and postimplementation groups did not differ significantly ( Table 1 ). The frequencies of positive PF4 test results, positive SRA results, and documented thrombi before the initiation of DTI therapy were similar between the groups.
Effectiveness and safety outcomes are summarized in Table 2 . The time to attainment of a target aPTT value was shorter in the postimplementation group than in the preimplementation group (3.4 hours versus 7.7 hours, p = 0.009), and the postimplementation group was in the target aPTT range for a greater proportion of the total DTI therapy than the preimplementation group (93% versus 81%, p = 0.001). The rate of new thrombosis after initiation of DTI therapy (as measured using documentation in the medical record), bleeding rates, and overall mortality rates were similar between groups. There were significant decreases in the frequencies of prescribing and total medication errors after implementation of the DTI protocol (Table 3). Among the 25 patients receiving DTI therapy before the initiation of the program, medication errors stemming from prescribing or administration mistakes had occurred in 10 (40%); errors occurred in only 3 (12%) of the patients treated per the DTI protocol (p = 0.05). Before the DTI program, prescribing errors occurred in 6 patients (24%) receiving DTI therapy. Following the advent of the protocol and the pharmacyto-dose program, prescribing errors were completely eliminated (p = 0.02). The difference between groups in the rate of administration errors was not significant (p = 1.00).
Discussion
A CDTM service has been defined as "a collaborative practice agreement between one or more physicians and pharmacists wherein qualified pharmacists working within the context of a defined protocol are permitted to assume professional responsibility for performing patient assessments; ordering drug therapy-related laboratory tests; administering drugs; and selecting, initiating, monitoring, continuing, and adjusting drug regimens." 5 Wong and colleagues 6 described the successful implementation of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and dosage adjustment. In a single-center cohort study, the investigators assessed the postimplementation outcomes associated with the pharmacist-driven CDTM service. They noted that the target International Normalized Ratio value was achieved within five days in 88% of patient cases managed by the CDTM service, as compared with 38% of patients treated before implementation of the service. While CDTM services and nomograms associated with oral anticoagulation have proved beneficial over the last decade, to date there are few articles that describe a successful pharmacydriven CDTM service focused on anticoagulation with DTI agents. In a study published in 2009, Ansara and colleagues 7 reported their experience using an argatroban dosing algorithm created at their institutions. The purpose of the study was to evaluate the anticoagulant effect and incidence of bleeding or thrombosis in patients receiving argatroban using a weight-based nomogram. The study included 51 patients, with 17 classified as critically ill or as having hepatic impairment. The authors explained the dosing algorithm as it applied to different patient populations and the outcomes associated with the pharmacy-driven nomogram. Based on the results of their study, using a weight-based nomogram to help guide dosing strategies for patients requiring anticoagulation with argatroban is an effective method for achieving and maintaining appropriate anticoagulation.
Am J Health-Syst Pharm-Vol 69 Nov 15, 2012
In addition, a recent study conducted by To and colleagues 8 reviewed the impact of a pharmacistdirected anticoagulation service (PDAS) on the safety and efficacy of DTI use in inpatients with HIT. The study included 193 patients, and the primary endpoints included the time to attainment of a therapeutic aPTT and the percentage of total treatment time during which aPTT values remained in the goal range. Secondary endpoints included the frequency of bleeding and the appropriateness of warfarin initiation. Results from this study showed that pharmacist involvement in the management of DTI therapy significantly shortened the mean time to therapeutic aPTT attainment and increased the mean percentage of total treatment time during which aPTT values were within the therapeutic range. Bleeding rates were decreased in the PDAS-managed group relative to a control group receiving usual care, but the decrease not considered significant. The appropriateness of warfarin initiation was also found to be similar between groups. Overall, the authors concluded that the implementation of the PDAS was associated with improved dosing and monitoring and a lower bleeding risk.
In the last report highlighted here, Kiser and colleagues 9 evaluated outcomes associated with a nomogrambased DTI management program. In their observational study, a group of 130 patients were observed to determine the time to attainment of goal aPTT values using a hospitalcreated nomogram relative to the time to attainment of goal aPTT values in a historical control group. Findings from the study showed that nomogram-based management of DTI therapy resulted in a shortened time to achieve goal aPTTs, a reduced number of dosage adjustments, a reduced time to dose stabilization, and an improved percentage of aPTT values within the goal range. Those results were similar to ours in terms of efficacy and safety outcomes, as rates of bleeding and mortality were similar in the two groups. However, our study also found a reduction in medication errors, specifically those at the prescribing level.
Results from these studies highlight the benefits of CDTM services for anticoagulation in the inpatient setting and promote continued collaborative practice interventions to maintain therapy optimization and improved patient outcomes. However, our study describes the outcomes associated with a pharmacist-driven multidisciplinary DTI service using argatroban and bivalirudin. With the advent of this protocol and the CDTM service, we have successfully decreased the average time required to achieve a therapeutic aPTT while also decreasing medication errors. To our knowledge, this is the first study to look at the percentage of medication errors before and after implementation of a pharmacist-driven CDTM service, which is important when dealing with high-risk medications such as DTIs.
Our study had several limitations that are worthy of mention. Before the implementation of the DTI program, the target aPTT range for argatroban was considered to be 1.5-3 times the baseline aPTT, 10 and the range for bivalirudin was 1.5-2.5 times the baseline aPTT. 11 However, for increased ease of use, it was determined that the target aPTT range for the two DTIs on formulary would be 50-80 seconds. 3 A narrower target range would be expected to create greater challenges in achieving an extended period of time within that range; however, our results show that the protocol was associated with an increased percentage of time within the range as well as a shorter time to reach the range.
Another limitation of our study involved the postimplementation patient population. The fact that the postimplementation group had a higher mean age, higher expected mortality, longer expected LOS, and greater need for continuous renal replacement therapy than the preimplementation group (although none of these differences was significant) could suggest that the patients in the postimplementation group had a higher acuity of illness at the time of hospitalization.
Nevertheless, clinical outcomes, including hospital LOS and mortality, did not differ significantly between the two groups, suggesting that the DTI protocol did not have a negative impact on clinical outcomes. A retrospective power analysis was conducted for the primary outcomes (i.e., the time to target aPTT attainment and the percentage of time within the target range) using a two-tailed test; the results of the analysis indicated a 79.7% chance and a 94.7% chance that the study methodology would detect a difference between the two means, respectively.
Finally, other limitations include a potential for inconsistency in data collection, the retrospective nature of the study, and the relatively small sample size. Data were collected by one individual for the preimplementation group and by another for the postimplementation group. Thus, the interpretation of progress notes, nursing records, and documentation by clinicians may have varied between the two individuals. In addition, the retrospective nature of the study and the small sample size limited our ability to adequately measure all the appropriate clinical outcomes.
It is important to note that there were low frequencies of positive PF4 test results, SRA results, and documented thrombosis before treatment with DTI therapy among the evaluated patient cases. The diagnosis of HIT on the basis of serologic tests may be controversial among clinicians, as the specificity and sensitivity of such assays may vary, potentially leading to unnecessary alterations in therapy. Thus, many clinicians choose to make the clinical diagnosis of HIT based on patient-specific factors and situations. However, it is also necessary to assess the risks and benefits associated with DTI therapy and ensure appropriate identification of those patients in whom therapy is truly indicated. As we continue to promote and improve this CDTM service, pharmacists will continue to educate fellow health care providers regarding the appropriateness of DTI therapy.
In addition to the positive effectiveness and safety outcomes, the CDTM service made significant progress in further developing professional relationships with other health care providers and redefining the role of the clinical pharmacists at our institution.
Conclusion
A pharmacist-driven DTI program resulted in improved effectiveness and safety outcomes, as demonstrated by improved attainment of target aPTT values and a decreased frequency of medication errors.
